ReviewCurrent urology reports2018
Improving the Specificity of PSA Screening with Serum and Urine Markers.
Review in Current urology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Primary healthcare-friendly prostate cancer prediction model using routine clinical parameters: a multicenter study.Frontiers in oncology · 2026Article
- A Modular Customizable Ligand-Conjugate (LC) System Targeting GhrelinBiomolecules · 2025Article
- Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays.European urology open science · 2024Article
- Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms.Journal of proteome research · 2023Article
- A Label-Free Proteomic Approach for the Identification of Biomarkers in the Exosome of Endometrial Cancer Serum.Cancers · 2022Article
- Kinetic Analysis of Prostate-Specific Antigen Interaction with Monoclonal Antibodies for Development of a Magnetic Immunoassay Based on Nontransparent Fiber Structures.Molecules (Basel, Switzerland) · 2022Article
- Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics.Metabolites · 2021Review
- The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p.Cancer biomarkers : section A of Disease markers · 2021Article
- Article
- Screening for Prostate Cancer.The Medical clinics of North America · 2020Review
- Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).Journal of Korean medical science · 2020Article
- Biomarkers in the setting of benign prostatic hyperplasia-induced lower urinary tract symptoms: what an interventional radiologist needs to know.The British journal of radiology · 2020Review
- Proteomic Analysis of Exosomes for Discovery of Protein Biomarkers for Prostate and Bladder Cancer.Cancers · 2020Review
- A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers.Cancers · 2020Article
- The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy.Biomedicines · 2020Article
- Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.Cancers · 2020Article
- Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel.Clinical epigenetics · 2019Article
- Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine.British journal of cancer · 2019Article
- Assessment of men's risk thresholds to proceed with prostate biopsy for the early detection of prostate cancer.International urology and nephrology · 2019Article
- Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewProstate cancer remains a significant public health burden. In order to decrease the morbidity and mortality associated with prostate cancer, serum prostate-specific antigen (PSA) screening has been used since the 1990s. However, there is concern for overdiagnosis of prostate cancer with widespread PSA screening, which could lead to overtreatment and its attendant morbidities. RECENT
findingsIn order to avoid unnecessary biopsy and downstream effects including treatment of insignificant prostate cancer, a number of tests have been proposed to improve upon PSA screening. Increasing the specificity of prostate cancer screening above that of PSA testing should reduce the incidence of unnecessary prostate biopsy. However, an increase in specificity is associated with a decrease in sensitivity, so these tests must be balanced with the concern for missing the diagnosis of potentially significant disease. In this context, we present a review of six common biomarkers proposed to improve the specificity of prostate cancer screening-free PSA, prostate health index, 4Kscore, PCA3, Select MDx, and ExoDx Prostate(Intelliscore).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.